48
Participants
Start Date
July 26, 2021
Primary Completion Date
May 4, 2022
Study Completion Date
May 4, 2022
Capivasertib
Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.
Rabeprazole
Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.
Research Site, Berlin
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
AstraZeneca
INDUSTRY